surmount-1 tirzepatide obesity nejm 2022 weight loss percent SURPASS-2 (NEJM 2021) was the definitive head-to-head: vs semaglutide 1.0 mg (the maximum approved T2DM dose) in 1,879 patients with type 2 diabetes. All three tirzepatide doses produced superior HbA1c reductions Precision obesity medicine: A phenotype-guided

Professor Vlado Perkovic, who presented the results for the first time today at the 61 st ERA Congress, emphasised the importance of these results, The use of semaglutide in people with type 2 diabetes and chronic kidney disease can lower the risk of major kidney outcomes and reduce the risk of cardiovascular events, cardiovascular death and all-cause death

Although total lean mass (baseline 51.3 kg) was also reduced by 2.3 kg and 1.5 kg with semaglutide and canagliflozin, respectively (estimated treatment difference: 0.78 [1.61, 0.04]), the proportion of lean mass (baseline 59.4%) increased by 1.2%- and 1.1%-point, respectively (estimated treatment difference 0.14 [0.89, 1.17])

The UACR should be checked at least annually, or more frequently in patients with chronic kidney disease

26 GechevT